Rafael Holdings full-year net loss $122.8M on $114.2M impairment; Q4 loss narrows to $4.6M

For the three months ended July 31, 2022, we incurred a net loss from continuing operations of $4.6 million, or $0.24 per share, which includes $1.2 million in non-cash stock-based compensation expense. For the same period in the prior year, we incurred a net loss from continuing operations of $12.2 million, or $0.75 per share, which included $5.6 million in non-cash stock-based compensation expense. Our revenues from continuing operations for the three months ended July 31, 2022, amounted to $0.07 million, compared to revenues of $0.19 million for the same period in the prior year.

For the twelve months ended July 31, 2022, we incurred a net loss from continuing operations of $122.8 million or $6.22 per share, w hich includes an impairment of cost method investment and losses from loans and receivables from Cornerstone Pharmaceuticals, Inc. (formerly Rafael Pharmaceuticals, Inc.) totaling $114.2 million. For the same period in the prior year, we incurred a net loss from continuing operations of $22.8 million, or $1.38 per share which included $6.6 million in non-cash stock-based compensation expense. Our revenues from continuing operations for the twelve months ended July 31, 2022, amounted to $0.4 million compared to $0.8 million in the same period in the prior year.